All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
At the 59th American Society of Hematology (ASH) Annual Meeting, Atlanta, GA, Eunice S. Wang, MD, from Roswell Park Cancer Institute, Buffalo, NY, presented results from a phase II trial, which assessed the tolerability and efficacy of crenolanib, a highly selective type I tyrosine kinase inhibitor of FLT3, in combination with standard induction chemotherapy in newly diagnosed FLT3-mutated AML patients ≤ 60 years old.
In total, 44 patients ≤ 60 years with newly diagnosed FLT3-mutated AML were enrolled in this trial. Patients were administered standard chemotherapy (cytarabine [100 mg/m2 for 7 Days] and either daunorubicin [90 mg/m2] or idarubicin [12 mg/m2] for 3 Days) in combination with crenolanib (100 mg TID was administered continuously starting on Day 9 of chemotherapy cycle). The results from 29 patients treated in this phase II study were reported.
MRD was measured by multi-parameter flow cytometry in bone marrow samples in CR/CRi patients (n = 16) at count recovery.
In total, 22 patients received consolidation therapy consisting of high-dose cytarabine plus crenolanib (n = 18), allo-HSCT (n = 15) and crenolanib maintenance (n = 13)
In an interview with the AGP, the speaker, Eunice Wang, discussed the findings of this phase II study where she highlighted that crenolanib in combination with standard induction and consolidation chemotherapy was “extremely well tolerated” and induced a “very good” response in patients ≤ 60 years with de novo FLT3 mutant AML.
Based on the findings of this phase II study, a phase III randomized study (NCT03258931) which is comparing the efficacy of crenolanib versus midostaurin in combination with standard induction and consolidation chemotherapy in newly diagnosed AML patients with FLT3 mutation is scheduled to start accrual in early 2018”. The primary endpoint of this study is Event Free Survival (EFS).
References